Your Search Returned 13 tagged news reports
The day that some speculated might never arrive finally came...The deal is set to be closed on September 4 for $1.82 per share...Shopping for synergies Spectrum clearly is shopping for synergies with the Allos buy. The doctors who prescribe Spectrum'
Stock buybacks are generally considered a bullish signal on Wall Street. They return capital to shareholders, while declaring management's belief that its own cheap shares are its best return on investment. As long as profits remain consistent, share
Since we looked at Allos Therapeutics last year , the company has kept its four-point score. With a tender offer on the table, though, it appears that shareholders may not be able to wait much longer for Allos to try to reach perfection. Allos is an
Font Resize Spectrum Pharmaceuticals said Thursday it signed an agreement to acquire Westminster-based Allos Therapeutics Inc...Spectrum, based in Henderson, Nev., will pay $1.82 per share for each outstanding share of Allos, a 28 percent premium
AG urges investors to back Allos acquisition. The Denver Post Posted: 10/13/2011 01:00:00 AM MDT AMAG Pharmaceuticals Inc., maker of the anemia drug Feraheme, urged investors Wednesday to support its $179 million bid for Westminster-based cancer
Pharmaceuticals Inc., dropped to a record low after saying a second bid by a rival company was withdrawn. Allos, based in Westminster, fell 18 percent to $1.43 Monday, after touching $1.38, the lowest price since the stock began trading in March 2000.
Therapeutics Inc. said Monday that a drug company it has not named withdrew an acquisition bid but that it is still in discussions to sell itself to Amag Pharmaceuticals Inc. Amag agreed to acquire Allos in July in an all-stock deal valued at $268
A score of 4 isn't going to heal all of Allos Therapeutics' wounds. Unlike many of its peers, the company has a promising product already with approval from the Food and Drug Administration, but it needs to reach a broader audience to deliver
The tie up allows Allos to commercialize Folotyn in the US and Canada, whereas Mundipharma will commercialize the drug in all other countries. As per the terms of the agreement, Mundipharma is responsible to pay a sum of $50m to Allos including and
Naturally, we want you to look a bit closer at these stocks before buying. You can get low-priced appliances in the dent-and-ding section of your home-remodeling superstore, but their quality might not be so good. Same thing here: Make sure there's